Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Peter J, Halfmann"'
Autor:
Amie J. Eisfeld, Lindsey N. Anderson, Shufang Fan, Kevin B. Walters, Peter J. Halfmann, Danielle Westhoff Smith, Larissa B. Thackray, Qing Tan, Amy C. Sims, Vineet D. Menachery, Alexandra Schäfer, Timothy P. Sheahan, Adam S. Cockrell, Kelly G. Stratton, Bobbie-Jo M. Webb-Robertson, Jennifer E. Kyle, Kristin E. Burnum-Johnson, Young-Mo Kim, Carrie D. Nicora, Zuleyma Peralta, Alhaji U. N’jai, Foday Sahr, Harm van Bakel, Michael S. Diamond, Ralph S. Baric, Thomas O. Metz, Richard D. Smith, Yoshihiro Kawaoka, Katrina M. Waters
Publikováno v:
Scientific Data, Vol 11, Iss 1, Pp 1-34 (2024)
Abstract Human infections caused by viral pathogens trigger a complex gamut of host responses that limit disease, resolve infection, generate immunity, and contribute to severe disease or death. Here, we present experimental methods and multi-omics d
Externí odkaz:
https://doaj.org/article/150f2ad7d6bb4178aa94bba0ca48d3b5
Autor:
Peter J. Halfmann, Kiyoko Iwatsuki-Horimoto, Makoto Kuroda, Yuichiro Hirata, Seiya Yamayoshi, Shun Iida, Ryuta Uraki, Mutsumi Ito, Hiroshi Ueki, Yuri Furusawa, Yuko Sakai-Tagawa, Maki Kiso, Tammy Armbrust, Sam Spyra, Ken Maeda, Zhongde Wang, Masaki Imai, Tadaki Suzuki, Yoshihiro Kawaoka
Publikováno v:
Communications Biology, Vol 7, Iss 1, Pp 1-7 (2024)
Abstract During the Omicron wave, previous variants such as BA.2, BA.4, and BA.5 were replaced by newer variants with additional mutations in the spike protein. These variants, BA.4.6, BQ.1.1, and XBB, have spread in different countries with differen
Externí odkaz:
https://doaj.org/article/7b6dc5728b27475ca7af06992e1a8732
Autor:
Peter J. Halfmann, Kathryn Loeffler, Augustine Duffy, Makoto Kuroda, Jie E. Yang, Elizabeth R. Wright, Yoshihiro Kawaoka, Ravi S. Kane
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract The 2002 SARS outbreak, the 2019 emergence of COVID-19, and the continuing evolution of immune-evading SARS-CoV-2 variants together highlight the need for a broadly protective vaccine against ACE2-utilizing sarbecoviruses. While updated vari
Externí odkaz:
https://doaj.org/article/65296e863059488f805a3afd0540a6c6
Autor:
Brock Kingstad-Bakke, Thomas Cleven, Hailey Bussan, Boyd L. Yount Jr., Ryuta Uraki, Kiyoko Iwatsuki-Horimoto, Michiko Koga, Shinya Yamamoto, Hiroshi Yotsuyanagi, Hongtae Park, Jay S. Mishra, Sathish Kumar, Ralph S. Baric, Peter J. Halfmann, Yoshihiro Kawaoka, M. Suresh
Publikováno v:
JCI Insight, Vol 8, Iss 22 (2023)
Although SARS-CoV-2 evolution seeds a continuous stream of antibody-evasive viral variants, COVID-19 mRNA vaccines provide robust protection against severe disease and hospitalization. Here, we asked whether mRNA vaccine–induced memory T cells limi
Externí odkaz:
https://doaj.org/article/f44f7ba048a84820a16413e36ed38855
Autor:
Ryuta Uraki, Shun Iida, Peter J. Halfmann, Seiya Yamayoshi, Yuichiro Hirata, Kiyoko Iwatsuki-Horimoto, Maki Kiso, Mutsumi Ito, Yuri Furusawa, Hiroshi Ueki, Yuko Sakai-Tagawa, Makoto Kuroda, Tadashi Maemura, Taksoo Kim, Sohtaro Mine, Noriko Iwamoto, Rong Li, Yanan Liu, Deanna Larson, Shuetsu Fukushi, Shinji Watanabe, Ken Maeda, Zhongde Wang, Norio Ohmagari, James Theiler, Will Fischer, Bette Korber, Masaki Imai, Tadaki Suzuki, Yoshihiro Kawaoka
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-11 (2023)
Omicron subvariants may differ in their replicative fitness and their potential to cause more severe disease. In this study, the authors characterized Omicron BA.2.75 in a hamster model and found that it replicates more efficiently in the lungs than
Externí odkaz:
https://doaj.org/article/9b470aadf40f4e12978de00269fa763e
Autor:
Peter J. Halfmann, Ryuta Uraki, Makoto Kuroda, Kiyoko Iwatsuki-Horimoto, Seiya Yamayoshi, Mutsumi Ito, Yoshihiro Kawaoka
Publikováno v:
EBioMedicine, Vol 93, Iss , Pp 104677- (2023)
Summary: Background: Like its predecessors in the XBB family, XBB.1.5 is highly immune evasive from therapeutic monoclonal antibodies and neutralizing antibodies generated by vaccination and/or infection. However, there is a lack of in vivo data on X
Externí odkaz:
https://doaj.org/article/4c3e86bd1fe04c29b93f6c7ff2090e30
Autor:
James Brett Case, Samantha Mackin, John M. Errico, Zhenlu Chong, Emily A. Madden, Bradley Whitener, Barbara Guarino, Michael A. Schmid, Kim Rosenthal, Kuishu Ren, Ha V. Dang, Gyorgy Snell, Ana Jung, Lindsay Droit, Scott A. Handley, Peter J. Halfmann, Yoshihiro Kawaoka, James E. Crowe, Daved H. Fremont, Herbert W. Virgin, Yueh-Ming Loo, Mark T. Esser, Lisa A. Purcell, Davide Corti, Michael S. Diamond
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
SARS-CoV-2 variants of concern are less susceptible to therapeutic neutralizing antibodies, given mutations in the surface glycoprotein S. Here, Case et al. show that therapeutic antibodies S309 and AZD7442 reduce lung infection with SARSCoV-2 Omicro
Externí odkaz:
https://doaj.org/article/8a854a9e359e4ddf9ea916e8a8feb054
Autor:
Siriruk Changrob, Peter J. Halfmann, Hejun Liu, Jonathan L. Torres, Joshua J.C. McGrath, Gabriel Ozorowski, Lei Li, G. Dewey Wilbanks, Makoto Kuroda, Tadashi Maemura, Min Huang, Nai-Ying Zheng, Hannah L. Turner, Steven A. Erickson, Yanbin Fu, Atsuhiro Yasuhara, Gagandeep Singh, Brian Monahan, Jacob Mauldin, Komal Srivastava, Viviana Simon, Florian Krammer, D. Noah Sather, Andrew B. Ward, Ian A. Wilson, Yoshihiro Kawaoka, Patrick C. Wilson
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 8 (2023)
The rapid evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants has emphasized the need to identify antibodies with broad neutralizing capabilities to inform future monoclonal therapies and vaccination strateg
Externí odkaz:
https://doaj.org/article/18492c6385494d56a88d5b525e7475bc
Autor:
Adrianus C M Boon, Tamarand L Darling, Peter J Halfmann, John Franks, Richard J Webby, Dan H Barouch, Julia R Port, Vincent J Munster, Michael S Diamond, Yoshihiro Kawaoka
Publikováno v:
PLoS Pathogens, Vol 18, Iss 12, p e1010970 (2022)
Externí odkaz:
https://doaj.org/article/6f2a1a67c8524d3ea255a5230a0af59d
Autor:
Peter J. Halfmann, Steven J. Frey, Kathryn Loeffler, Makoto Kuroda, Tadashi Maemura, Tammy Armbrust, Jie E. Yang, Yixuan J. Hou, Ralph Baric, Elizabeth R. Wright, Yoshihiro Kawaoka, Ravi S. Kane
Publikováno v:
EBioMedicine, Vol 86, Iss , Pp 104341- (2022)
Summary: Background: The COVID-19 pandemic continues to cause morbidity and mortality worldwide. Most approved COVID-19 vaccines generate a neutralizing antibody response that primarily targets the highly variable receptor-binding domain (RBD) of the
Externí odkaz:
https://doaj.org/article/d7471206528645209e55180d68b770cc